American Association of Immunologists (AAI) Annual Meeting 2026

/in ,

Barouch Lab highlighted in the Boston AAI History timeline for  research leading to

J&J vaccine for COVID-19

Long COVID involves activation of proinflammatory and immune exhaustion pathways

/in , ,

Aid M, Boero-Teyssier V, McMahan K, Dang R, Doyle M, Belabbaci N, Borducchi E, Collier AY, Mullington J, Barouch DH. Long COVID involves activation of proinflammatory and immune exhaustion pathways. Nat Immunol. 2026 Jan;27(1):61-71. doi: 10.1038/s41590-025-02353-x. Epub 2025 Dec 12. Erratum in: Nat Immunol. 2026 Jan 23. doi: 10.1038/s41590-026-02438-1. PMID: 41388153; PMCID: PMC12764429.

Anti-IL-15 treatment reduces acute lentivirus inflammation and signaling in the brain

/in , ,

Ram DR, Gopalakrishnan RM, Aid M, Kroll K, Miftahof J, Aristizabal O, Gikundiro EK, Davis C, Hefti MM, Fiock KL, Tilahun B, Umutoniwase Y, Loidolt K, Fennessey CM, Mercado NB, Harper-Alexander V, Jones R, Woolley G, Varner V, Lifton M, Bosinger SE, Barouch DH, Keele BF, Reeves RK, Tan CS. Anti-IL-15 treatment reduces acute lentivirus inflammation and signaling in the brain. Cell Rep Med. 2026 Jan 20;7(1):102567. doi: 10.1016/j.xcrm.2025.102567

Associations between the microbiome and immune responses to an adenovirus-based HIV-1 candidate vaccine are distinct between African and US cohorts

/in

Li Y, Stieh DJ, Droit L, Kim AH, Rodgers R, Mihindukulasuriya KA, Wang L, Pau MG, Yuan O, Virgin HW, Barouch DH, Baldridge MT, Handley SA. Associations between the microbiome and immune responses to an adenovirus-based HIV-1 candidate vaccine are distinct between African and US cohorts. mSystems. 2026 Jan 15:e0143525. doi: 10.1128/msystems.01435-25. Epub ahead of print. PMID: 41537600.

Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants

/in

Lasrado N, Rössler A, McConnell I, Molloy K, Bhowmik R, Happle C, Guan R, McMahan K, Pereira J, Liu J, Borducchi E, Wang L, Shah K, Wixted B, Stankov MV, Dopfer-Jablonka A, Collier AY, Behrens GMN, Barouch DH. Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants. Vaccine. 2026 Jan 1;69:127997. doi: 10.1016/j.vaccine.2025.127997. Epub 2025 Nov 19. PMID: 41265004; PMCID: PMC12643176.

Minor SHIV variants abrogate protective efficacy of broadly neutralizing antibodies in rhesus macaques

/in ,

Walker-Sperling VEK, Nkolola J, Liu J, Aid M, Julg B, Seaman MS, Barouch DH. Minor SHIV variants abrogate protective efficacy of broadly neutralizing antibodies in rhesus macaques. Nat Commun. 2025 Dec 18;16(1):11226. doi: 10.1038/s41467-025-66321-7. PMID: 41413011; PMCID: PMC12714793.

Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines

/in

Vidal SJ, Lasrado N, Tostanoski LH, Chaudhari J, Mbiwan ER, Neka GD, Strutton EA, Espinosa Perez AA, Sellers D, Barrett J, Lifton M, Wakabayashi S, Eshaghi B, Borducchi EN, Aid M, Li W, Scriba TJ, Jaklenec A, Langer R, Barouch DH. Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines. Cell. 2025 Nov 26;188(24):6791-6803.e13. doi: 10.1016/j.cell.2025.08.027. Epub 2025 Sep 15. PMID: 40957415; PMCID: PMC12445596.

Immunopathogenesis of lethal H5N1 avian influenza virus clade 2.3.4.4b infection in macaques

/in ,

Andersen H, Aid M, Stone JJ, Lyons CE, Berlied A, Nkolola J, Lasrado N, Peterson M, Pessaint L, Kitajewski C, Yalley-Ogunro J, Porto M, Stone R, Cabus M, Valentin D, Van Ry A, Narvaez B, Orekov T, Kar S, Teow E, Kouneski K, Ferreira A, Velasco J, Campbell R, Henderson C, Beah W, Patel G, Finneyfrock B, Cook A, Paul S, Haasnoot J, Ramirez-Carvajal L, Koldijk MH, Arias Rivas S, Koch CM, Goudsmit J, Lewis MG, Martinot AJ, Barouch DH. Immunopathogenesis of lethal H5N1 avian influenza virus clade 2.3.4.4b infection in macaques. Immunity. 2025 Sep 9;58(9):2157-2165.e5. doi: 10.1016/j.immuni.2025.07.020. Epub 2025 Aug 18. PMID: 40829590.

A Novel Approach for Preventing Respiratory Virus Infections

/in

Vidal SJ, Barouch DH. A Novel Approach for Preventing Respiratory Virus Infections. JAMA Intern Med. 2025;185(11):1317–1318. doi:10.1001/jamainternmed.2025.4297

Corrigendum to ‘Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study’. EBioMedicine 2024;108: 105320

/in

Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, Zhang L, Mielke D, Khuzwayo S, Omar FL, Stanfield-Oakley S, Keyes T, Dunn B, Goodman D, Fong Y, Benkeser D, Zou R, Hural J, Hyrien O, Juraska M, Luedtke A, van der Laan L, Giorgi EE, Magaret C, Carpp LN, Pattacini L, van de Kerkhof T, Korber B, Willems W, Fisher LH, Schuitemaker H, Swann E, Kublin JG, Pau MG, Buchbinder S, Tomaka F, Nijs S, Lavreys L, Gelderblom HC, Corey L, Mngadi K, Gray GE, Borducchi E, Hendriks J, Seaton KE, Zolla-Pazner S, Barouch DH, Ferrari G, De Rosa SC, McElrath MJ, Andersen-Nissen E, Stieh DJ, Tomaras GD, Gilbert PB; Imbokodo Study and Correlates Group. Corrigendum to ‘Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study’. EBioMedicine 2024;108: 105320. EBioMedicine. 2025 Sep;119:105874. doi: 10.1016/j.ebiom.2025.105874. Epub 2025 Aug 23. Erratum for: EBioMedicine. 2024 Oct;108:105320. doi: 10.1016/j.ebiom.2024.105320. PMID: 40850015; PMCID: PMC12789700.